In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

A hot off the press summary of the TRITON trial by PR Committee member Professor Freek W.A. Verheugt



The sensational news on Sunday 4 November was the TRITON trial which demonstrated that in 13,608 STEMI/non STEMI patients treated invasively and followed for a year with prasugrel versus clopodigrel, the stronger prasugrel led to significantly less myocardal infarctions, yet had no incidence on strokes or deaths.


Stent thrombosis was halved by prasugrel compared to clopidogrel. However severe bleeding was increased by 32% by prasugrel which may hamper its general use in interventional therapy for (N)STEMI patients.